mvjrМедицинский вестник Юга РоссииMedical Herald of the South of Russia2219-80752618-7876The Rostov State Medical Universitymvjr-1253Research ArticleОБЗОРЫREVIEWМеханизмы резистентности к терапии хронического миелолейкоза ингибитором тирозинкиназ иматинибомThe Mechanisms of Resistance to Tyrosine Kinase Inhibitor Imatinib Therapy of Chronic Myeloid LeukemiaКуцевС. И.KutsevS. I.

Лаборатория медицинской генетики

344022, г. Ростов-на-Дону, пер. Нахичеванский 29

Laboratory of Medical Genetics

29 Nakhichevansky st., Rostov-on-Don, 344022

kutsev@mail.ruМордановС. В.MordanovS. V.

Лаборатория медицинской генетики

344022, г. Ростов-на-Дону, пер. Нахичеванский 29

Laboratory of Medical Genetics

29 Nakhichevansky st., Rostov-on-Don, 344022

ЗельцерА. Н.ZeltserA. N.

Лаборатория медицинской генетики

344022, г. Ростов-на-Дону, пер. Нахичеванский 29

Laboratory of Medical Genetics

29 Nakhichevansky st., Rostov-on-Don, 344022

ОксенюкО. С.OxenjukO. S.

Лаборатория медицинской генетики

344022, г. Ростов-на-Дону, пер. Нахичеванский 29

Laboratory of Medical Genetics

29 Nakhichevansky st., Rostov-on-Don, 344022

УстаеваО. А.UstaevaO. A.

Лаборатория медицинской генетики

344022, г. Ростов-на-Дону, пер. Нахичеванский 29

Laboratory of Medical Genetics

29 Nakhichevansky st., Rostov-on-Don, 344022

КунгуроваТ. И.KungurovaT. I.

Лаборатория медицинской генетики

344022, г. Ростов-на-Дону, пер. Нахичеванский 29

Laboratory of Medical Genetics

29 Nakhichevansky st., Rostov-on-Don, 344022

БурнашеваЕ. В.BurnashevaE. V.

кафедра гематологии и трансфузиологии ФПК и ППС

344022, г. Ростов-на-Дону, пер. Нахичеванский 29

Department of Hematology and Transfusiology

29 Nakhichevansky st., Rostov-on-Don, 344022

ГранкинаЕ.GrankinaE.

кафедра гематологии и трансфузиологии ФПК и ППС

344022, г. Ростов-на-Дону, пер. Нахичеванский 29

Department of Hematology and Transfusiology

29 Nakhichevansky st., Rostov-on-Don, 344022

ШатохинЮ. В.ShatokhinYu. V.

кафедра гематологии и трансфузиологии ФПК и ППС

344022, г. Ростов-на-Дону, пер. Нахичеванский 29

Department of Hematology and Transfusiology

29 Nakhichevansky st., Rostov-on-Don, 344022

Ростовский государственный медицинский университетРоссияRostov State Medical UniversityRussian Federation201030062010021017Copyright © Куцев С.И., Морданов С.В., Зельцер А.Н., Оксенюк О.С., Устаева О.А., Кунгурова Т.И., Бурнашева Е.В., Гранкина Е., Шатохин Ю.В., 20102010Куцев С.И., Морданов С.В., Зельцер А.Н., Оксенюк О.С., Устаева О.А., Кунгурова Т.И., Бурнашева Е.В., Гранкина Е., Шатохин Ю.В.Kutsev S.I., Mordanov S.V., Zeltser A.N., Oxenjuk O.S., Ustaeva O.A., Kungurova T.I., Burnasheva E.V., Grankina E., Shatokhin Y.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.medicalherald.ru/jour/article/view/1253

Новым стандартом терапии Ph-позитивного хронического миелолейкоза (ХМЛ) является лечение иматинибом – селективным игибитором Bcr-Abl тирозинкиназы. Лечение иматинибом пациентов в хронической фазе ХМЛ приводит к достижению гематологической и цитогенетической ремиссии с большой частотой. Однако, у некоторых пациентов с ХМЛ наблюдается первичная или приобретенная резистентность к иматинибу. В обзоре обсуждаются различные механизмы развития резистентности к терапии иматинибом и их клиническое значение.

Imatinib mesylate is a potent and high selective inhibitor of Bcr-Abl tyrosine kinase, which is established now as the standard of Philadelphia chromosome positive (Ph) chronic myeloid leukemia (CML) treatment. The treatment of patients with chronic phase of CML with imatinib has resulted in high rates of hematologic and cytogenetic responses. Nevertheless, primary and acquired resistance have been observed in few CML patients. The mechanisms of resistance to imatinib and its clinical significance were discussed in this review.

хронический миелоидный лейкозингибиторы тирозинкиназмеханизмы резистентностиChronic myeloid leukemiatyrosine kinase inhibitorsmechanisms of resistanceReferencesO’Brien S.G., Guilhot F., Goldman J.M. et al. International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM) // Blood. – 2008. – V. 112, № 11. – Р.186.O’Brien S.G., Guilhot F., Goldman J.M. et al. International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM) // Blood. – 2008. – V. 112, № 11. – Р.186.de Lavallade H., Apperley J.F., Khorashad J.S. et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis // J. Clin. Oncol. – 2008. – V.26, № 20. – P.3358-3363.de Lavallade H., Apperley J.F., Khorashad J.S. et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis // J. Clin. Oncol. – 2008. – V.26, № 20. – P.3358-3363.Gorre M.E., Mohammed M., Ellwood K. et al. Clinical resistance to STI-571 cancer therapy caused by BCR–ABL gene mutation or amplification // Science. – 2001. – V.293, №5531. – P.876–880.Gorre M.E., Mohammed M., Ellwood K. et al. Clinical resistance to STI-571 cancer therapy caused by BCR–ABL gene mutation or amplification // Science. – 2001. – V.293, №5531. – P.876–880.Roche-Lestienne C., Soenen-Cornu V., Grardel-Duflos N. et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment // Blood. – 2002. – V.100, № 3. – P.1014–1018.Roche-Lestienne C., Soenen-Cornu V., Grardel-Duflos N. et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment // Blood. – 2002. – V.100, № 3. – P.1014–1018.Shah N.P., Nicoll J.M., Nagar B. et al. Multiple BCR–ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia // Cancer Cell. – 2002. – V.2, № 2. – P.117–125.Shah N.P., Nicoll J.M., Nagar B. et al. Multiple BCR–ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia // Cancer Cell. – 2002. – V.2, № 2. – P.117–125.Hochhaus A. Cytogenetic and molecular mechanisms of resistance to imatinib // Semin. Hematol. – 2003. – V.40, № 2, Suppl 2. – P.69-79.Hochhaus A. Cytogenetic and molecular mechanisms of resistance to imatinib // Semin. Hematol. – 2003. – V.40, № 2, Suppl 2. – P.69-79.Куцев С.И., Морданов С.В. Амплификация гена BCR-ABL у пациентов с хроническим миелоидным лейкозом, рефрактерных к иматинибу // Онкогематология. – 2009, №3. – С. 57-61.Куцев С.И., Морданов С.В. Амплификация гена BCR-ABL у пациентов с хроническим миелоидным лейкозом, рефрактерных к иматинибу // Онкогематология. – 2009, №3. – С. 57-61.Branford S., Rudzki Z., Walsh S. et al. Detection of BCR–ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis // Blood. – 2003. – V.102, №1. – P.276–283.Branford S., Rudzki Z., Walsh S. et al. Detection of BCR–ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis // Blood. – 2003. – V.102, №1. – P.276–283.Nicolini F.E., Corm S., Le Q.H. et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP) // Leukemia. – 2006. – V.20, №6. – P.1061-1066.Nicolini F.E., Corm S., Le Q.H. et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP) // Leukemia. – 2006. – V.20, №6. – P.1061-1066.Redaelli S., Piazza R., Rostagno R. et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants // J. Clin. Oncol. – 2009. – V.20, № 27(3). – P.469-471.Redaelli S., Piazza R., Rostagno R. et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants // J. Clin. Oncol. – 2009. – V.20, № 27(3). – P.469-471.1Куцев С.И., Вельченко М.В. Значение анализа мутаций гена BCR-ABL в оптимизации таргетной терапии хронического миелолейкоза // Клиническая онкогематология. – 2008. – Т. 1, №3. – С. 190-199.1Куцев С.И., Вельченко М.В. Значение анализа мутаций гена BCR-ABL в оптимизации таргетной терапии хронического миелолейкоза // Клиническая онкогематология. – 2008. – Т. 1, №3. – С. 190-199.Marktel S., Marin D., Foot N. et al. Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression // Haematologica. – 2003. – Vol.88, №3. – P.260-267.Marktel S., Marin D., Foot N. et al. Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression // Haematologica. – 2003. – Vol.88, №3. – P.260-267.O’Dwyer M.E., Mauro M.J., Blasdel C. et al. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate // Blood. – 2004. – Vol.103, №2. – P.451-455.O’Dwyer M.E., Mauro M.J., Blasdel C. et al. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate // Blood. – 2004. – Vol.103, №2. – P.451-455.Домрачева ЕВ, Захарова А.Е., Асеева Е.А. Прогностическое значение дополнительных цитогенетических аномалий при хроническом миелолейкозе // Гематол. и трансфузиол. – 2005. – Т. 50, №4. – С. 37-41Домрачева ЕВ, Захарова А.Е., Асеева Е.А. Прогностическое значение дополнительных цитогенетических аномалий при хроническом миелолейкозе // Гематол. и трансфузиол. – 2005. – Т. 50, №4. – С. 37-41Мартынкевич И.С., Мартыненко Л.С., Иванова М.П. и др. Дополнительные хромосомные аберрации у больных хроническим миелолейкозом // Гематол. и трансфузиол. – 2007. – Т. №2. – С. 28-35.Мартынкевич И.С., Мартыненко Л.С., Иванова М.П. и др. Дополнительные хромосомные аберрации у больных хроническим миелолейкозом // Гематол. и трансфузиол. – 2007. – Т. №2. – С. 28-35.Cortes J.E., Talpaz M., Giles F. et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy // Blood. – 2003. – Vol.101, №10. – P. 3794-3800.Cortes J.E., Talpaz M., Giles F. et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy // Blood. – 2003. – Vol.101, №10. – P. 3794-3800.Куцев С.И., Морданов С.В., Зельцер А.Н. Прогностическое значение дополнительных хромосомных аномалий в Phпозитивных клетках в терапии иматинибом хронического миелолейкоза / // Медицинская генетика. – 2009. – № 10. – С. 27-33.Куцев С.И., Морданов С.В., Зельцер А.Н. Прогностическое значение дополнительных хромосомных аномалий в Phпозитивных клетках в терапии иматинибом хронического миелолейкоза / // Медицинская генетика. – 2009. – № 10. – С. 27-33.Peng B., Hayes M., Resta D. et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients // J. Clin. Oncol. – 2004. – V.22, № 5. – P. 935-942.Peng B., Hayes M., Resta D. et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients // J. Clin. Oncol. – 2004. – V.22, № 5. – P. 935-942.Larson R.A., Druker B.J., Guilhot F. et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study // Blood. – 2008. – V.111, №8. – P. 4022-4028.Larson R.A., Druker B.J., Guilhot F. et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study // Blood. – 2008. – V.111, №8. – P. 4022-4028.Picard S., Titier K., Etienne G. et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia // Blood. – 2007. – V.109, № 8. – P. 3496-3499.Picard S., Titier K., Etienne G. et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia // Blood. – 2007. – V.109, № 8. – P. 3496-3499.Singh N., Kumar L., R. Meena, T. Velpandian. Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders // Eur. J. Clin. Pharmacol. – 2009. – V.65, № 6. – P.545-549Singh N., Kumar L., R. Meena, T. Velpandian. Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders // Eur. J. Clin. Pharmacol. – 2009. – V.65, № 6. – P.545-549Wilkinson G.R. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans // J. Pharmacokinet. Biopharm. – 1996. – V. 24, № 5. – P.475-490.Wilkinson G.R. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans // J. Pharmacokinet. Biopharm. – 1996. – V. 24, № 5. – P.475-490.Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib // Clin Pharmacokinet. – 2005. – V.44, № 9. – P. 879-894.Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib // Clin Pharmacokinet. – 2005. – V.44, № 9. – P. 879-894.Bolton A.E., Peng B., Hubert M. et al. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects// Cancer Chemother. Pharmacol. – 2004. – V.53, № 2. – P.102-106Bolton A.E., Peng B., Hubert M. et al. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects// Cancer Chemother. Pharmacol. – 2004. – V.53, № 2. – P.102-106Куцев С.И., Оксенюк О.С. Лекарственный мониторинг в терапии хронического миелолейкоза иматинибом // Клиническая онкогематология. – 2009. – Т. 2, № 3. – С. 256-261.Куцев С.И., Оксенюк О.С. Лекарственный мониторинг в терапии хронического миелолейкоза иматинибом // Клиническая онкогематология. – 2009. – Т. 2, № 3. – С. 256-261.Tsang J., Rudychev L., Pescatore S.L. Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM)// J.Clin. Oncol. – 2006. – V. 24, №18S – P. 6119.Tsang J., Rudychev L., Pescatore S.L. Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM)// J.Clin. Oncol. – 2006. – V. 24, №18S – P. 6119.StCharles M.St., Bollu V., Hornyak E. et al. Predictors of treatment non-adherence in patients treated with Imatinib mesylate for chronic myeloid leukemia // Blood. – V.114, №22. – P. 870.StCharles M.St., Bollu V., Hornyak E. et al. Predictors of treatment non-adherence in patients treated with Imatinib mesylate for chronic myeloid leukemia // Blood. – V.114, №22. – P. 870.28. Куцев С.И., Шатохин Ю.В. Влияние перерывов терапии иматинибом на достижение цитогенетического и молекулярного ответов у больных хроническим миелолейкозом // Казан. мед. журн. – 2009. – Т. 90, №6. – C. 827-831.28. Куцев С.И., Шатохин Ю.В. Влияние перерывов терапии иматинибом на достижение цитогенетического и молекулярного ответов у больных хроническим миелолейкозом // Казан. мед. журн. – 2009. – Т. 90, №6. – C. 827-831.Mahon F.-X., Picard S., Marit G., Robinson P., Molimard M. Use of therapeutic drug monitoring in CML patients on imatinib// Blood. – 2007. – V.110,№ 5. – P. 1701.Mahon F.-X., Picard S., Marit G., Robinson P., Molimard M. Use of therapeutic drug monitoring in CML patients on imatinib// Blood. – 2007. – V.110,№ 5. – P. 1701.Куцев С.И., Оксенюк О.С., Кравченко Е.Г. и др. Лекарственный мониторинг терапии хронического миелолейкоза иматинибом // Клиническая онкогематология. – 2010. – Т. 3, № 1. – С. 1-9.Куцев С.И., Оксенюк О.С., Кравченко Е.Г. и др. Лекарственный мониторинг терапии хронического миелолейкоза иматинибом // Клиническая онкогематология. – 2010. – Т. 3, № 1. – С. 1-9.Thomas J., Wang L., Clark R.E., Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance // Blood. – 2004. – V.104, №12. – P. 3739-3745.Thomas J., Wang L., Clark R.E., Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance // Blood. – 2004. – V.104, №12. – P. 3739-3745.White D.L., Saunders V.A., Dang P. et al.OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to Imatinib // Blood. – 2006. – V.108, №2. – P.697-704.White D.L., Saunders V.A., Dang P. et al.OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to Imatinib // Blood. – 2006. – V.108, №2. – P.697-704.Crossman L.C., Druker B.J., Deininger M.W. et al. hOCT 1 and resistance to imatinib // Blood. – 2005. – V.106, №3. – P. 1133-1134.Crossman L.C., Druker B.J., Deininger M.W. et al. hOCT 1 and resistance to imatinib // Blood. – 2005. – V.106, №3. – P. 1133-1134.Wang L., Giannoudis A., Lane S. et al. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia // Clin. Pharmacol. Ther. – 2008. – V.83, №2. – Р.258-264.Wang L., Giannoudis A., Lane S. et al. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia // Clin. Pharmacol. Ther. – 2008. – V.83, №2. – Р.258-264.Baccarani M., Cortes J., Pane F. et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet // J. Clin. Oncol. – 2009. – V.27, №35. – P. 6041-6051.Baccarani M., Cortes J., Pane F. et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet // J. Clin. Oncol. – 2009. – V.27, №35. – P. 6041-6051.

The authors declare that there are no conflicts of interest present.